Myriad Genetics (MYGN) Operating Leases (2019 - 2026)

Myriad Genetics has disclosed Operating Leases across 8 years of filings, most recently posting $84.1 million for Q1 2026.

• In Q1 2026, Operating Leases fell 3.78% year-over-year to $84.1 million; the TTM figure through Mar 2026 stood at $84.1 million (down 3.78% YoY), while the FY2025 annual figure was $83.0 million, down 5.57% from the prior year.
• Operating Leases improved to $84.1 million in Q1 2026, from $83.0 million in the prior quarter.
• Over the last five years, Operating Leases for MYGN reached as high as $130.9 million in Q4 2022 and fell as low as $5.9 million in Q1 2023.
• The 5-year median for Operating Leases is $87.4 million (2022), against an average of $77.8 million.
• Annual changes were most pronounced in 2023 — Operating Leases tumbled 95.21% — and 2024, when it jumped 1498.31%.
• A 5-year view of Operating Leases shows it stood at $130.9 million in 2022, then declined by 25.59% to $97.4 million in 2023, then fell by 9.75% to $87.9 million in 2024, then retreated by 5.57% to $83.0 million in 2025, then advanced by 1.33% to $84.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $84.1 million, $83.0 million, and $84.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.